| Nov 25 | Feb 26 | May 26 | Aug 26 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Buy | — | — | — | — | — | — | — | — | — | — | — | — |
| Sell | — | — | — | — | — | — | — | — | — | — | — | — |
| total | individual payouts | |
|---|---|---|
| 2026 | 1.47 |
—
—
|
| 2025 | 1.42 |
—
—
—
—
|
| 2024 | 1.41 |
—
—
—
—
|
| 2023 | 1.40 |
—
—
—
—
|
| 2022 | 1.39 |
—
—
—
—
|
| 2021 | 1.38 |
—
—
—
—
|
| 2020 | 1.37 |
—
—
—
—
|
| 2019 | 1.35 |
—
—
—
—
|
| 2018 | 1.31 |
—
—
—
—
|
| 2017 | 1.27 |
—
—
—
—
|
| 2016 | 1.23 |
—
—
—
—
|
| 2024 | 2025 | 2026 | Q'26 | |
|---|---|---|---|---|
| Cash | 83.25 | 85.88 | 75.62 | 106.43 |
| Receivables | 224.20 | 228.41 | 244.16 | 210.73 |
| Inventory | 26.22 | 22.88 | 19.27 | 18.47 |
| Other | — | — | — | — |
| 454.04 | 439.88 | 419.67 | 438.22 |
| 2024 | 2025 | 2026 | Q'26 | |
|---|---|---|---|---|
| Payables | 55.66 | 60.95 | 67.20 | 44.94 |
| ST’ Debt | 7.50 | 10.00 | 12.50 | 13.75 |
| Other | 483.78 | 462.69 | 451.42 | 384.28 |
| 873.28 | 820.86 | 778.95 | 688.82 |
| 10y | 5y | 3y | |
| Sales | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Cash Flow | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Earnings | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Book Value | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ |
| Jul | Oct | Jan | Apr | Year | |
|---|---|---|---|---|---|
| ’26 | 386.36 | — | — | — |
—
|
| ’26 | 396.80 | 421.75 | 410.04 | 447.94 |
1,676.53
|
| ’25 | 403.81 | 426.60 | 404.63 | 442.58 |
1,677.61
|
| ’24 | 451.01 | 492.81 | 460.71 | 468.46 |
1,872.99
|
| ’23 | 487.57 | 514.84 | 491.37 | 526.13 |
2,019.90
|
| ’22 | 488.39 | 533.00 | 515.88 | 545.65 |
2,082.93
|
| ’21 | 431.33 | 491.01 | 482.91 | 536.25 |
1,941.50
|
| Jul | Oct | Jan | Apr | Year | |
|---|---|---|---|---|---|
| ’26 | (55.27) | — | — | — |
—
|
| ’26 | (85.00) | 8.50 | 179.82 | 157.21 |
260.52
|
| ’25 | (88.71) | (5.28) | 146.24 | 150.34 |
202.59
|
| ’24 | (82.33) | (1.15) | 107.84 | 183.29 |
207.64
|
| ’23 | (89.94) | 13.74 | 129.91 | 223.35 |
277.07
|
| ’22 | (84.77) | 9.15 | 234.11 | 180.62 |
339.10
|
| ’21 | (120.78) | 44.16 | 231.45 | 205.10 |
359.92
|
| Jul | Oct | Jan | Apr | Year | |
|---|---|---|---|---|---|
| ’26 | (70.27) | — | — | — |
—
|
| ’26 | (99.90) | (18.30) | 277.60 | 137.87 |
307.54
|
| ’25 | (106.56) | (22.88) | 117.76 | 130.64 |
118.25
|
| ’24 | (106.17) | (28.76) | 85.49 | 159.01 |
112.53
|
| ’23 | (113.69) | (10.75) | 104.55 | 210.16 |
188.54
|
| ’22 | (104.98) | (17.94) | 203.73 | 145.81 |
226.62
|
| ’21 | (145.07) | 21.02 | 203.60 | 177.02 |
256.56
|
| Jul | Oct | Jan | Apr | Year | |
|---|---|---|---|---|---|
| ’26 | (0.23) | — | — | — |
—
|
| ’26 | 0.22 | 0.84 | 0.56 | 2.61 |
4.16
|
| ’25 | (0.03) | 0.74 | (0.43) | 1.25 |
1.53
|
| ’24 | (1.67) | (0.35) | (2.08) | 0.46 |
(3.65)
|
| ’23 | (0.32) | 0.68 | (1.29) | 1.22 |
0.31
|
| ’22 | 0.24 | 0.99 | 0.63 | 0.76 |
2.62
|
| ’21 | 0.29 | 1.22 | 0.39 | 0.73 |
2.63
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | 36.57 | 28.84 | 30.45 | 29.93 | 28.38 | — | — | — |
Low Price
|
| ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 58.20 | 49.58 | 53.96 | 47.26 | 57.45 | — | — | — |
High Price
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 9,500 | 8,800 | 6,400 | 5,200 | 4,500 | — | — | — |
Employees
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 0.22 | 0.23 | 0.29 | 0.32 | 0.37 | — | — | — |
Revenue/Emp
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2,082.93 | 2,019.90 | 1,872.99 | 1,677.61 | 1,676.53 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 66.36% | 65.71% | 69.05% | 74.29% | 74.26% | — | — | — |
Gross Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 209.66 | 33.10 | (187.05) | 142.88 | 215.09 | — | — | — |
EBT
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 10.07% | 1.64% | (9.99%) | 8.52% | 12.83% | ‡‡‡ | ‡‡‡ | — |
EBT Margin
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 148.31 | 17.23 | (200.32) | 84.16 | 221.62 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Net Income
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 215.17 | 313.86 | 286.65 | 148.21 | 146.25 | — | — | — |
Depreciation
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 37.36 | 36.36 | 34.09 | 31.04 | 31.95 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Revenue/Sh
|
| ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡ | 2.66 | 0.31 | (3.65) | 1.56 | 4.22 | ‡‡‡‡ | ‡‡‡‡ | — |
Earnings/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 6.08 | 4.99 | 3.78 | 3.75 | 4.97 | — | — | — |
Cash Flow/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (2.02) | (1.59) | (1.73) | (1.56) | 0.90 | ‡‡‡ | ‡‡‡ | — |
Capex/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.06 | 3.39 | 2.05 | 2.19 | 5.86 | — | — | — |
Free CF/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 20.49 | 18.81 | 13.46 | 13.92 | 16.17 | — | — | — |
Book Value/Sh
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 55.76 | 55.56 | 54.95 | 54.05 | 52.47 | ‡‡‡‡‡ | ‡‡‡‡‡ | — |
Shares
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡ | ‡‡‡‡‡ | 18.85 | 123.26 | 0.00 | 27.97 | 9.54 | ‡‡‡‡ | ‡‡‡‡ | — |
PE Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.34 | 1.05 | 1.10 | 1.41 | 1.28 | ‡‡‡ | ‡‡‡ | — |
PS Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 2.45 | 2.03 | 2.79 | 3.14 | 2.53 | ‡‡‡ | ‡‡‡ | — |
PB Ratio
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1.67 | 1.37 | 1.47 | 1.83 | 1.64 | ‡‡‡‡ | ‡‡‡‡ | — |
EV/Sales
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 15.37 | 14.66 | 24.49 | 25.39 | 9.28 | — | — | — |
EV/FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 339.10 | 277.07 | 207.64 | 202.59 | 260.52 | ‡‡‡ | ‡‡‡ | — |
Op' Cash Flow
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (112.48) | (88.53) | (95.11) | (84.34) | 47.02 | — | — | — |
Capex
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 226.62 | 188.54 | 112.53 | 118.25 | 307.54 | — | — | — |
FCF
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | (418.55) | (354.27) | (419.24) | (380.97) | (359.28) | — | — | — |
Working Cap'
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 787.03 | 748.29 | 774.60 | 799.44 | 683.40 | — | — | — |
Total Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 686.63 | 641.58 | 691.35 | 713.55 | 607.78 | — | — | — |
Net Debt
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 1,142.27 | 1,045.03 | 739.72 | 752.21 | 848.24 | — | — | — |
Sh' Equity
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 4.36% | 0.53% | (6.87%) | 3.11% | 8.39% | — | — | — |
ROA
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 7.49% | 2.07% | 2.28% | 9.44% | 11.88% | — | — | — |
ROIC
|
| ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | ‡‡‡‡‡ | 13.28% | 1.58% | (22.45%) | 11.28% | 27.69% | — | — | — |
ROE
|
John Wiley & Sons (WLY), a stalwart in academic publishing, faces a precarious crossroads for conservative investors after a decade of revenue peaks, sharp declines, and episodic losses amid industry disruptions like open-access mandates and AI tools. Once expanding from $1.73 billion in 2016 to $2.08 billion in 2022 through acquisitions and digital shifts, revenues have since plummeted 7.3% to $1.87 billion in 2024, with forecasts signaling further drops to $1.68 billion in 2025 before meager stabilization. Aggressive workforce cuts—from 9,500 to 5,200 employees—have boosted revenue per employee to $323,000 and gross margins to a projected 74.3%, but profitability swings wildly, with 2024 net losses at $200 million contrasting brighter 2025-2027 earnings outlooks of $84-$190 million.
The balance sheet raises red flags: shareholders’ equity eroded 37% since 2022 to $752 million, net debt climbed to $714 million, and free cash flow per share halved to $2.19 amid steady leverage. Stock trades at depressed levels—104% below consensus targets—with elevated P/E multiples and insider selling (over $770,000 in 2025) underscoring skepticism, especially post-restructuring and a planned Research Publishing spin-off that carries execution risks.
While analysts envision a turnaround with EPS reaching $3.63 by 2027 and ROE rebounding to 11.3%, tail risks loom large—revenue erosion, FCF vulnerability, and competitive threats demand vigilance. Risk-averse portfolios should await sub-10x P/E confirmation and insider buys before engaging, prioritizing balance sheet resilience over speculative upside.
Keep track of companies that you follow and research.
Full access to our data with predictions and indicators that we calculate daily.
Full access to our screener with tons of custom values and customizable email notifications.
Excel export of financials and screeners you define and save.